How proinflammatory cytokines may impair growth and cause muscle wasting

Hormone Research

Volumn 67, Issue SUPPL. 1, 2007, Pages 64-70

  Thissen, Jean Paul ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Cytokines; Growth hormone resistance; Growth retardation; Insulin like growth factor I; Skeletal muscle

Indexed keywords

CYTOKINE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CYTOKINE PRODUCTION; GROWTH RETARDATION; HORMONAL REGULATION; HORMONE RESISTANCE; IMMUNOPATHOGENESIS; INFLAMMATION; LIVER; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRESS;

EID: 33847030647     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097555     Document Type: Conference Paper

References (75)

1. Ballinger AB, Azooz O, El Haj T, Poole S, Farthing MJ: Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000;46:694-700.
2. Spate U, Schulze PC: Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7:265-269.
3. Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
4. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N: Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195-200.
5. Briard N, Guillaume V, Frachebois C, Rico-Gomez M, Sauze N, Oliver C, Dutour A: Endotoxin injection increases growth hormone and somatostatin secretion in sheep. Endocrinology 1998;139:2662-2669.
6. Daniel JA, Elsasser TH, Martinez A, Steele B, Whitlock BK, Sartin JL: Interleukin-1beta and tumor necrosis factor-alpha mediation of endotoxin action on growth hormone. Am J Physiol Endocrinol Metab 2005;289:E650-E657.
7. Gong FY, Deng JY, Shi YF: Stimulatory effect of interleukin-1beta on growth hormone gene expression and growth hormone release from rat GH3 cells. Neuroendocrinology 2005;81:217-228.
8. Soto L, Martín AI, Millán S, Vara E, López- Calderón A: Effects of endotoxin lipopolysaccharide administration on the somatotropic axis. J Endocrinol 1998;159:239-246.
9. Wada Y, Sato M, Niimi M, Tamaki M, Ishida T, Takahara J: Inhibitory effects of interleukin-1 on growth hormone secretion in conscious male rats. Endocrinology 1995;136:3936-3941.
10. Peisen JN, McDonnell KJ, Mulroney SE, Lumpkin MD: Endotoxin-induced suppression of the somatotropic axis is mediated by interleukin-1beta and corticotrophin-releasing factor in the juvenile rat. Endocrinology 1995;136:3378-3390.
11. Hataya Y, Akamizu T, Hosoda H, Kanamoto N, Moriyama K, Kangawa K, Takaya K, Nakao K: Alterations of plasma ghrelin levels in rats with lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome. Endocrinology 2003;144:5365-5371.
12. Van den Berghe G, De Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY: The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997;82:590-599.
13. Dahn MS, Lange MP, Jacobs LA: Insulin-like growth factor-I production is inhibited in human sepsis. Arch Surg 1988;123:1409-1414.
14. Defalque D, Brandt N, Ketelslegers JM, Thissen JP: GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am J Physiol 1999;276:E565-E572.
15. Bergad PL, Schwarzenberg SJ, Humbert JT, Morrison M, Amarasinghe S, Towle HC, Berry SA: Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 2000;279:C1906-C1917.
16. Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL: Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol 2003;284:G646-G654.
17. Difedele LM, He J, Bonkowski EL, Han X, Held MA, Bohan A, Menon RK, Denson LA: Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology 2005;128:1278-1291.
18. Schaefer F, Chen Y, Tsao T, Nouri P, Rabkin R: Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. J Clin Invest 2001;108:467-475.
19. Waxman DJ, Ram PA, Park S-H, Choi HK: Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription. J Biol Chem 1995;270:13262-13270.
20. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR: STAT5b is required for GH-induced liver Igf-I gene expression. Endocrinology 2001;142:3836-3841.
21. Woelfle J, Rotwein P: In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab 2004;286:E393-E401.
22. Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN: Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am J Physiol Endocrinol Metab 2002;283:E472-E481.
23. Mao YL, Ling PR, Fitzgibbons TP, McCowen KC, Frick GP, Bistrian BR, Smith RJ: Endotoxin-induced inhibition of growth hormone receptor signaling in rat liver in vivo. Endocrinology 1999;140:5505-5515.
24. Wolf M, Böhm S, Brand M, Kreymann G: Proinflammatory cytokines interleukin 1b and tumor necrosis factor a inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996;135:729-737.
25. Thissen JP, Verniers J: Inhibition by interleukin-1b and tumor necrosis factor-a of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 1997;138:1078-1084.
26. Boisclair YR, Wang JR, Shi JR, Hurst KR, Ooi GT: Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1b on the growth hormone-dependent transcription of the acidlabile subunit gene in liver cells. J Biol Chem 2000;275:3841-3847.
27. Lelbach A, Scharf JG, Ramadori G: Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein-1, -3 and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J Hepatol 2001;35:558-567.
28. Fan J, Char D, Bagby GJ, Gelato MC, Lang CH: Regulation of insulin-like growth factor-I (IGF-I) and IGF binding proteins by tumor necrosis factor. Am J Physiol 1995;269:R1204-R1212.
29. Lang CH, Fan J, Cooney R, Vary TC: IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol Endocrinol Metab 1996;270:E430-E437.
30. Denson LA, Menon RK, Shaufl A, Bajwa HS, Williams CR, Karpen SJ: TNF-a downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. J Clin Invest 2001;107:1451-1458.
31. Ram PA, Waxman DJ: SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999;274:35553-35561.
32. Colson A, Le Cam A, Maiter D, Edery M, Thissen JP: Potentiation of growth hormone-induced liver suppressors of cytokine signaling messenger ribonucleic acid by cytokines. Endocrinology 2000;141:3687-3695.
33. Lang CH, Hong-Brown L, Frost RA: Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance. Pediatr Nephrol 2005;20:306-312.
34. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E: Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I - a model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-650.
35. Frystyk J, Gronbæk H, Skjærbæk C, Flyvbjerg A, Orskov H, Baxter RC: Developmental changes in serum levels of free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit in rats. Endocrinology 1998;139:4286-4292.
36. Binoux M, Hossenlopp P: Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 1988;67:509-514.
37. Bar RS, Clemmons DR, Boes M, Busby WH, Booth BA, Dake BL, Sandra A: Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart. Endocrinology 1990;127:1078-1086.
38. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
39. Elgin RG, Busby WHJ, Clemmons DR: An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 1987;84:3254-3258.
40. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR: Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989;125:766-772.
41. Ernst M, Rodan GA: Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 1990;127:807-814.
42. Burch WW, Correa J, Shively JE, Powell DR: The 25-kilodalton insulin-like growth factor (IGF)-binding protein inhibits both basal and IGF-I-mediated growth of chick embryo pelvic cartilage in vitro. J Clin Endocrinol Metab 1990;70:173-180.
43. Ross M, Francis GL, Szabo L, Wallace JC, Ballard FJ: Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-I and IGF-II but not des-(1-3)-IGF-I. Biochem J 1989;258:267-272.
44. De Mellow JS, Baxter RC: Growth hormone dependent insulin-like growth factor binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in skin fibroblasts. Biochem Biophys Res Commun 1988;156:199-204.
45. Fan J, Molina PE, Gelato MC, Lang CH: Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 1994;134:1685-1692.
46. Lang CH, Fan J, Frost RA, Gelato MC, Sakurai Y, Herndon DN, Wolfe RR: Regulation of the insulin-like growth factor system by insulin in burn patients. J Clin Endocrinol Metab 1996;81:2474-2480.
47. Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, Clemmons DR: Insulin-like growth factor binding protein-3 proteolytic activity is induced following elective surgery. J Clin Endocrinol Metab 1992;75:590-595.
48. Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W, Hinds CJ: Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 1996;24:1460-1466.
49. Skjaerbaek C, Frystyk J, Orskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, Moller N, Flyvbjerg A: Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 1998;83:2445-2449.
50. Fan J, Char D, Kolasa AJ, Pan W, Maitra SR, Patlak CS, Spolarics Z, Gelato MC, Lang CH: Alterations in hepatic production and peripheral clearance of IGF-I after endotoxin. Am J Physiol Endocrinol Metab 1995;269:E33-E42.
51. Thissen JP, Davenport ML, Pucilowska J, Miles MV, Underwood LE: Increased serum clearance and degradation of 125I-labeled IGF-I in protein-restricted rats. Am J Physiol 1992;262:E406-E411.
52. Frost RA, Nystrom GJ, Lang CH: Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1b: requirement of the mitogen-activated protein kinase pathway. Endocrinology 2000;141:3156-3164.
53. Lang CH, Vary TC, Frost RA: Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology 2003;144:3922-3933.
54. Lang CH, Pollard V, Fan J, Traber LD, Traber DL, Frost RA, Gelato MC, Prough DS: Acute alterations in growth hormone insulin-like growth factor axis in humans injected with endotoxin. Am J Physiol Regul Integr Comp Physiol 1997;273:R371-R378.
55. Schulze PC, Gielen S, Adams V, Linke A, Mobius-Winkler S, Erbs S, Kratzsch J, Hambrecht R, Schuler G: Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure. Basic Res Cardiol 2003;98:267-274.
56. Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP: Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 2002;283:E1279-E1290.
57. Hong-Brown LQ, Brown CR, Cooney RN, Frost RA, Lang CH: Sepsis-induced muscle growth hormone resistance occurs independent of STAT5 phosphorylation. Am J Physiol Endocrinol Metab 2003;285:E63-E72.
58. Frost RA, Nystrom GJ, Lang CH: Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2002;283:R698-R709.
59. Hambrecht R, Schulze PC, Gielen S, Linke A, Mobius WS, Yu JT, Kratzsch J, Baldauf G, Busse MW, Schubert A, Adams V, Schuler G: Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol 2002;39:1175-1181.
60. Frost RA, Nystrom GJ, Lang CH: Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 2003;144:1770-1779.
61. Ding H, Gao XL, Hirschberg R, Vadgama JV, Kopple JD: Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest 1996;97:1064-1075.
62. Fang CH, Li BG, Sun X, Hasselgren PO: Insulin-like growth factor I reduces ubiquitin and ubiquitin-conjugating enzyme gene expression but does not inhibit muscle proteolysis in septic rats. Endocrinology 2000;141:2743-2751.
63. Vary TC, Dardevet D, Grizard J, Voisin L, Buffiere C, Denis P, Breuille D, Obled C: Differential regulation of skeletal muscle protein turnover by insulin and IGF-I after bacteremia. Am J Physiol Endocrinol Metab 1998;275:E584-E593.
64. Fang CH, Li BG, Wang JJ, Fischer JE, Hasselgren PO: Treatment of burned rats with insulin-like growth factor I inhibits the catabolic response in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 1998;275:R1091-R1098.
65. Fang CH, Li BG, James JH, King JK, Evenson AR, Warden GD, Hasselgren PO: Protein breakdown in muscle from burned rats is blocked by IGF-I and GSK-3{β} inhibitors. Endocrinology 2005;146:3141-3149.
66. Broussard SR, McCusker RH, Novakofski JE, Strle K, Hong SW, Johnson RW, Freund GG, Dantzer R, Kelley KW: Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology 2003;144:2988-2996.
67. Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW, Dantzer R, Kelley KW: IL-1beta impairs insulin-like growth factor-induced differentiation and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. J Immunol 2004;172:7713-7720.
68. Frost RA, Lang CH, Gelato MC: Transient exposure of human myoblasts to tumor necrosis factor-a inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 1997;138:4153-4159.
69. Strle K, Broussard SR, MCusker RH, Shen WH, Johnson RW, Freund GG, Dantzer R, Kelley KW: Proinflammatory cytokine impairment of IGF-I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 2004;145:4592-4602.
70. Layne MD, Farmer SR: Tumor necrosis factor-a and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. Exp Cell Res 1999;249:177-187.
71. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM: Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappa B. FASEB J 2001;15:1169-1180.
72. Fang CH, Li BG, Wray CJ, Hasselgren PO: Insulin-like growth factor-I inhibits lysosomal and proteasome-dependent proteolysis in skeletal muscle after burn injury. J Burn Care Rehabil 2002;23:318-325.
73. Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, Macgillivray C, Lee RT, Rosenthal N: Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005;97:418-426.
74. Schakman O, Gilson H, de Coninck V, Lause P, Verniers J, Havaux X, Ketelslegers JM, Thissen JP: Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 2005;146:1789-1797.
75. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P: Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005;115:451-458.